白三烯受体拮抗剂安可来治疗哮喘的临床研究

CLINICAL EVALUATION OF ZAFIRLUKAST,A LEUCOTRIENE RECEPTOR ANTAGONIST IN TREATMENT OF BRONCHIAL ASTHMA

目的 : 观察新型药物白三烯受体拮抗剂安可来对哮喘的防治作用及其不良反应。方法 : 6 3例轻、中度哮喘患者随机分为安可来组 38例 ,40mg/d ;曲尼斯特组 2 7例 ,30 0mg/d。共服用 6周。 结果 : 安可来组服药前后第 1秒用力呼气量 (FEV1.0 )由 (1.79± 0 .5 1)升至 (1.94± 0 .6 6 ) ,升幅 8.4% ;曲尼司特组由 (1.5 5± 0 .6 5 )升至 (1.6 5± 0 .83) ,升幅 6 .5 % ;安可来组 %FEV1.0升幅达 9.2 % ,明显高于曲尼司特组 3.3% (P <0 .0 5 ) ;安可来组在夜间憋醒次数与肺部体征方面明显少于曲尼司特组 ,但无显著差异 ;安可来组有 1例患者ALT轻度升高 ,停药 2周后降至正常 ;临床综合评价 ,安可来组有效率为 74.4% ,明显高于曲尼司特组 (5 6 .5 % )。结论 :安可来是一种治疗轻、中度哮喘的有效药物 ,患者有良好的依从性 ,肺功能改善明显 ,且不良反应少。

OBJECTIVE:To observe the prophylactic and therapeutic effect of Zafirlukast in treatment of asthma. METHODS:63 patients with mild to moderate asthma were divided to receive Zefirlukast in a daily dose of 40 mg( n =40) for 6 weeks,or Tranilast in daily dose of 300 mg( n =25) for 6 weeks.RESULTS:2 patients in the control group were discontinued from the study because of exacerbation of asthma. FEV1.0 increased from 1.79±0.51 to 1.94±0.66(18.4%) in active group and from 1.55±0.65 to 1.65±0.83(3.3%) in control group .%FEV1.0 improved more remarkably in activc group than that of control group. Clinical symptom scorcs were improved more obviously in active group but no significant difference between groups. The effective rate was 74.4% for active group and 56.5% for control group with less side effects.CONCLUSIONS: Zasirlukast,a leucotriene receptor antagonist,is an effective agent in treatment of mild to moderate asthma with less side effects.